|Efavirenz||Non-nucleoside reverse transcriptase inhibitor|
|Lamivudine||Nucleoside reverse transcriptase inhibitor|
|Tenofovir disoproxil||Nucleoside reverse transcriptase inhibitor|
|Defined daily dose||not established|
Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Telura, is a fixed-dose combination medication for the treatment of HIV/AIDS. It combines efavirenz, lamivudine, and tenofovir disoproxil. As of 2019[update], it is listed by the World Health Organization as an alternative first line option to dolutegravir/lamivudine/tenofovir. It is taken by mouth.
Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness. Severe side effects may include depression, psychosis, or osteonecrosis. In those with a history of epilepsy, it may increase the frequency of seizures. Greater care should also be taken in those with kidney problems. It is unclear if use during pregnancy is safe.
It is on the World Health Organization's List of Essential Medicines. A year of medication is estimated to costs 154 USD in the developing world as of 2011. The combination received tentative approval in the United States in 2014. Its availability and importance is supported by Medecins Sans Frontieres.
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 11 September 2020. CS1 maint: discouraged parameter (link)
- "Efavirenz + lamivudine + tenofovir disoproxil fumarate (Addition) -- Adults". World Health Organization (WHO).
- World Health Organization (July 2019). Policy brief: update of recommendations on first- and second-line antiretroviral regimens. World Health Organization. hdl:10665/325892. WHO/CDS/HIV/19.15. License: CC BY-NC-SA 3.0 IGO.
- "Telura" (PDF). Mylan.in. 2014. Retrieved 13 December 2017. CS1 maint: discouraged parameter (link)
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "HIV/AIDS History of Approvals - HIV/AIDS Historical Time Line 2010 - 2015". FDA. Retrieved 13 December 2017. CS1 maint: discouraged parameter (link)
- "Efavirenz". Drug Information Portal. U.S. National Library of Medicine.
- "Lamivudine". Drug Information Portal. U.S. National Library of Medicine.
- "Tenofovir disoproxil". Drug Information Portal. U.S. National Library of Medicine.
- "Tenofovir disoproxil fumarate". Drug Information Portal. U.S. National Library of Medicine.